Cancer immunotherapy efficacy is driven by tumour biology, not by its histology. Impact on drug development and approvals

Mélodie Bonvalet, François Xavier Danlos, Stéphane Champiat, Mathieu Rouanne, Aurélien Marabelle

Résultats de recherche: Contribution à un journal › Editorial

Accès au document

@article{8b2d35a3eb3f4bd59928ce1eac082601,

title = "Cancer immunotherapy efficacy is driven by tumour biology, not by its histology. Impact on drug development and approvals",

author = "M{\'e}lodie Bonvalet and Danlos, {Fran{\c c}ois Xavier} and St{\'e}phane Champiat and Mathieu Rouanne and Aur{\'e}lien Marabelle",

year = "2022",

month = feb,

day = "1",

doi = "10.1016/j.ejca.2021.12.004",

language = "English",

volume = "162",

pages = "130--132",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

TY - JOUR

T1 - Cancer immunotherapy efficacy is driven by tumour biology, not by its histology. Impact on drug development and approvals

AU - Bonvalet, Mélodie

AU - Danlos, François Xavier

AU - Champiat, Stéphane

AU - Rouanne, Mathieu

AU - Marabelle, Aurélien

PY - 2022/2/1

Y1 - 2022/2/1

UR - http://www.scopus.com/inward/record.url?scp=85122001492&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2021.12.004

DO - 10.1016/j.ejca.2021.12.004

M3 - Editorial

C2 - 34983015

AN - SCOPUS:85122001492

SN - 0959-8049

VL - 162

SP - 130

EP - 132

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -